Fig. 2: Efficacy of ABBV-706 and SEZ6 expression in R/R SCLC, including the 1.8 mg kg−1 and 2.5 mg kg−1 dose-optimization cohorts. | Nature Medicine

Fig. 2: Efficacy of ABBV-706 and SEZ6 expression in R/R SCLC, including the 1.8 mg kg−1 and 2.5 mg kg−1 dose-optimization cohorts.

From: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Fig. 2: Efficacy of ABBV-706 and SEZ6 expression in R/R SCLC, including the 1.8 mg kg−1 and 2.5 mg kg−1 dose-optimization cohorts.The alternative text for this image may have been generated using AI.

a, Best percentage change in target lesion size from baseline in the 1.8 mg kg−1 cohort (n = 41). b, Best percentage change in target lesion size from baseline in the 2.5 mg kg−1 cohort (n = 39). c, Response over time while on study in the 1.8 mg kg−1 cohort (n = 41). d, Response over time while on study in the 2.5 mg kg−1 cohort (n = 39). Distribution of SEZ6 expression between arms (e) and among non-responders and responders (f) in the 1.8 mg kg−1 and 2.5 mg kg−1 dose cohorts. Evaluable SEZ6 expression data were available for 38 of 47 patients with response assessment in the 1.8 mg kg−1 cohort and for 37 of 42 patients in the 2.5 mg kg−1 cohort. Data are presented as median H-score and interquartile range (IQR). 3L+, third line and beyond; CR, complete response; IHC, immunohistochemistry; PD, progressive disease; PR, partial response; SD, stable disease.

Back to article page